Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis
Recruitment status was: Recruiting
Idiopathic pulmonary fibrosis (IPF) is a diffuse lung disease, associated with the histological appearance of usual interstitial pneumonia (UIP), with an inexorably deteriorating clinical course. Prognosis is poor, reported median survival is less than 3 years. The prevalence is estimated as being 3 to 10 per 100.000 in different Western populations. To date, no pharmacological therapy has been proven to alter or reverse the pathogenic process of IPF. Most treatments trials have been observational case series of small patient populations and very few have been randomized, prospective and placebo-controlled.
Two recent Cochrane reviews investigated the role of corticosteroids and other immunomodulatory agents and concluded that there is no evidence for their use in IPF. Most current therapies are targeted to suppress the inflammatory component of the disease, based on the theory that it would be chronic alveolar inflammation which leads to parenchymal remodeling and fibrosis. Recently, a hypothesis that has gained acceptance suggests that fibrosis may result directly from alveolar injury, promoting an abnormal fibrogenic repair mediated by fibroblasts and myofibroblasts.
One of the cytotoxic agents most widely used and better tolerated in the management of IPF is azathioprine. Based upon limited data available and from a single small high quality randomized controlled trial (RCT), this drug appears to confer, given in conjunction with prednisone, a marginal long term survival advantage. Since this combination therapy is associated serious adverse effect, we planned to design a trial of low dose corticosteroid and azathioprine versus placebo in management of IPF, evaluating progression-free survival.
Our study hypothesis is: Combined therapy with azathioprine and corticosteroids improves progression-free survival in patients with the diagnosis of IPF.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: a Randomized, Double-Blind, Controlled Study|
- Progression-free survival, defined as free of death or a decrease from baseline in the FVC of at least 10%. [ Time Frame: 2 years ]
- Number of Acute Exacerbations of IPF. [ Time Frame: 2 years ]
- Health Related Quality of life, measured with the Chronic Questionnaire (CRQ). [ Time Frame: 2 years ]
- PO2 at rest and at exercise from baseline. [ Time Frame: 2 years ]
- P(A-a)O2 at rest and at exercise from baseline. [ Time Frame: 2 years ]
- Predicted FEV1 from baseline. [ Time Frame: 2 years ]
- Forced expiratory volume in one second (FEV1) to FVC from baseline. [ Time Frame: 2 years ]
- Plethysmographic lung volumes from baseline. [ Time Frame: 2 years ]
- Diffusion capacity for carbon monoxide (DLco) from baseline. [ Time Frame: 2 years ]
- Six-Minute Walk test, from baseline: resting and 6 minute SpO2, presence or absence of desaturation to 88% or lower at the end of the six minute walk, walked distance d. Pre and post modified Borg dyspnea scores [ Time Frame: 2 years ]
- Scoring of extent of lung fibrosis on HRCT, according to two independent chest radiologists, form baseline. [ Time Frame: 2 years ]
- Number and severity of adverse effects. [ Time Frame: 2 years ]
- Number of protocol drop outs. [ Time Frame: 2 years ]
|Study Start Date:||May 2005|
|Estimated Study Completion Date:||December 2008|
Placebo Comparator: 0
Active Comparator: 1
The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00518310
|Instituto Nacional del Tórax|
|Santiago, RM, Chile|
|Principal Investigator:||Florenzano Matías, MD||Clínica Las Condes|